How Do We Predict Anti-PD-1 Therapy Response in Melanoma?
A set of reproducible biomarkers are associated with better response rates to anti–PD-1 therapy in patients with advanced melanoma.
Can Rapid EGFR Testing Speed Up Treatment Initiation in Lung Cancer?
A rapid EGFR-specific assay allowed for quicker identification of EGFR mutation–positive NSCLC, and thus a shorter time to initiation of EGFR-directed therapy.
Tumor Vasculature Remains Stable Through Progression of Ovarian Cancer
The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.
Can Bevacizumab Be Recommended in High-Risk Melanoma?
Treatment of high-risk melanoma with adjuvant bevacizumab following resection improves disease-free survival over standard observation, but not overall survival.
Analysis Identifies Cutoff Point for ALK Positivity in Lung Cancer
Researchers identified the percentage cutoff for ALK positivity that is needed for clinical utility in ALK-positive NSCLC.
Does Analgesic Use Improve Survival in Ovarian Cancer?
Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.
High-Dose Glucocorticoids for Hypophysitis Are Worse in Melanoma Patients
Melanoma patients who were treated with glucocorticoids for ipilimumab-induced hypophysitis had improved survival outcomes if they received low doses.
Photodynamic Diagnosis of Bladder Cancer With Oral 5-ALA Is Feasible, Safe
TURBT with fluorescent light source using oral 5-ALA is well tolerated in non–muscle-invasive bladder cancer.
Poorer Survival, Higher Costs With Trimodal Therapy in Bladder Cancer
Patients with muscle-invasive bladder cancer who underwent trimodal therapy had significantly poorer survival than those who underwent radical cystectomy alone.
Cisplatin/Gemcitabine Shows Improvements in Worst Breast Cancer Subtype
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
Gardening Intervention Improves Outcomes Among Breast Cancer Survivors
The gardening intervention led to improvements in physical activity measures and other health outcomes in breast cancer survivors.
Improved Outcomes for Melanoma Brain Metastases With Added Immunotherapy
Immune checkpoint inhibitors initiated soon before or after radiosurgery offer excellent outcomes in patients with brain metastases originating from melanoma.
ASCO Updates Guideline on Management of HER2-Positive Breast Cancer
An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies.
Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma.
TRBV Gene Use Could Act as Biomarker in HER2+ Breast Cancer
Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.
BMI Inversely Associated With Risk of Premenopausal Breast Cancer
The inverse association with premenopausal breast cancer was seen across the entire distribution of BMI, and at a higher magnitude than previously reported.
MAGE-A3 Immunotherapeutic Fails in Stage III Melanoma
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma.
Genomic Analyses Reveal Dozens More Prostate Cancer Susceptibility Loci
A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
Metabolomic Analysis May Provide Non-Invasive Bladder Cancer Surveillance
A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.
FGFR Inhibitor Shows Promise in Advanced Urothelial Carcinoma
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Can Anxiety and Early Life Adversity Affect Ovarian Cancer Outcomes?
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.
Dacomitinib Improves OS in EGFR-Mutant NSCLC
Treatment with the second-generation EGFR TKI dacomitinib resulted in improved overall survival over gefitinib in patients with NSCLC and activating EGFR mutations.
Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
Nab-Paclitaxel/Carboplatin Should Be a First Option in TNBC
Nab-paclitaxel/carboplatin should be considered a first-line option in the setting of triple-negative breast cancer.
Olaparib/Abiraterone Combo Improves PFS in CRPC
The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?
Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2+ breast cancer.
Smoking-Related Lung Cancer Remains Elevated 25 Years After Quitting
Among former heavy smokers, the risk for lung cancer remains significantly increased compared with never-smokers, even more than 25 years since quitting.
Smoking at Time of Treatment Worsens Prostate Cancer Outcomes
Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including recurrence, metastasis, and mortality.
Secondary Surgery Fails to Improve Outcomes in Recurrent Ovarian Cancer
Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.
Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma.